1. Home
  2. VCIG vs AZTR Comparison

VCIG vs AZTR Comparison

Compare VCIG & AZTR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo VCI Global Limited

VCIG

VCI Global Limited

HOLD

Current Price

$0.84

Market Cap

4.0M

ML Signal

HOLD

Logo Azitra Inc

AZTR

Azitra Inc

HOLD

Current Price

$0.32

Market Cap

3.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
VCIG
AZTR
Founded
2013
2014
Country
Malaysia
United States
Employees
N/A
N/A
Industry
Diversified Commercial Services
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
4.0M
3.2M
IPO Year
2023
2023

Fundamental Metrics

Financial Performance
Metric
VCIG
AZTR
Price
$0.84
$0.32
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$4.00
AVG Volume (30 Days)
1.8M
1.1M
Earning Date
05-08-2026
02-23-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
0.98
N/A
Revenue
$32,903,041.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$0.87
N/A
Revenue Growth
24.77
N/A
52 Week Low
$0.51
$0.26
52 Week High
$978.00
$3.92

Technical Indicators

Market Signals
Indicator
VCIG
AZTR
Relative Strength Index (RSI) 49.53 52.27
Support Level $0.73 $0.26
Resistance Level $1.14 $0.31
Average True Range (ATR) 0.13 0.03
MACD 0.07 0.01
Stochastic Oscillator 53.04 64.28

Price Performance

Historical Comparison
VCIG
AZTR

About VCIG VCI Global Limited

VCI Global Ltd is a holding company. The principal activities of the Company and its subsidiaries are the provision of business Strategy consultancy and technology development. The firm organized its consulting services into three main segments: Business Strategy Consultancy; Technology development, solutions and consultancy; and Others. It derives the majority of its revenue from the Business Strategy Consultancy segment, which focuses on listing solutions, investor relations, and boardroom strategies consultancy.

About AZTR Azitra Inc

Azitra Inc is an early-stage clinical biopharmaceutical company focused on developing therapies for precision dermatology using engineered proteins and live biotherapeutic products. Its discovery platform is screened for naturally occurring bacterial cells with beneficial effects. These microbes are then genomically sequenced and engineered to make cellular therapies, recombinant therapeutic proteins, peptides, and small molecules for the precision treatment of dermatology diseases. The company's product candidates include ATR-12, for treating the orphan disease and Netherton syndrome; ATR-04, a genetically modified strain of S. epidermidis for treating the papulopustular rash; and ATR-01, a potential treatment for ichthyosis vulgaris, a chronic, abnormally dry, scaly skin disease.

Share on Social Networks: